Agoram B - Search Results

1

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.

Ly N, Zheng Y, Griffiths JM, van der Merwe R, Agoram B, Parnes JR, Roskos L. Ly N, et al. Among authors: agoram b. J Clin Pharmacol. 2021 Jul;61(7):901-912. doi: 10.1002/jcph.1803. Epub 2021 Jan 16. J Clin Pharmacol. 2021. PMID: 33368307 Clinical Trial.

2

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates .

Jain M, Doughty D, Clawson C, Li X, White N, Agoram B, van der Merwe R. Jain M, et al. Among authors: agoram b. Int J Clin Pharmacol Ther. 2017 Jul;55(7):606-620. doi: 10.5414/CP203023. Int J Clin Pharmacol Ther. 2017. PMID: 28590244 Free PMC article. Clinical Trial.

3

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.

Baverel PG, White N, Vicini P, Karlsson MO, Agoram B. Baverel PG, et al. Among authors: agoram b. Clin Pharmacol Ther. 2018 May;103(5):826-835. doi: 10.1002/cpt.803. Epub 2017 Sep 28. Clin Pharmacol Ther. 2018. PMID: 28758192 Clinical Trial.

4

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

Baverel PG, Jain M, Stelmach I, She D, Agoram B, Sandbach S, Piper E, Kuna P. Baverel PG, et al. Among authors: agoram b. Br J Clin Pharmacol. 2015 Dec;80(6):1337-49. doi: 10.1111/bcp.12725. Epub 2015 Oct 1. Br J Clin Pharmacol. 2015. PMID: 26182954 Free PMC article. Clinical Trial.

5

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

Agoram BM. Agoram BM. Br J Clin Pharmacol. 2009 Feb;67(2):153-60. doi: 10.1111/j.1365-2125.2008.03297.x. Epub 2008 Dec 11. Br J Clin Pharmacol. 2009. PMID: 19076987 Free PMC article.

6

A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.

Karelina T, Voronova V, Demin O, Colice G, Agoram BM. Karelina T, et al. Among authors: agoram bm. CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):608-616. doi: 10.1002/psp4.12129. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27885827 Free PMC article.

7

At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.

Penney M, Agoram B. Penney M, et al. Among authors: agoram b. Br J Clin Pharmacol. 2014 May;77(5):740-5. doi: 10.1111/bcp.12225. Br J Clin Pharmacol. 2014. PMID: 23962236 Free PMC article. Review.

8

Population pharmacokinetics of darbepoetin alfa in healthy subjects.

Agoram B, Sutjandra L, Sullivan JT. Agoram B, et al. Br J Clin Pharmacol. 2007 Jan;63(1):41-52. doi: 10.1111/j.1365-2125.2006.02752.x. Epub 2006 Aug 30. Br J Clin Pharmacol. 2007. PMID: 16939525 Free PMC article.

9

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.

Agoram B, Heatherington AC, Gastonguay MR. Agoram B, et al. AAPS J. 2006 Sep 1;8(3):E552-63. doi: 10.1208/aapsj080364. AAPS J. 2006. PMID: 17025273 Free PMC article. Clinical Trial.

10

Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.

Aston PJ, Derks G, Raji A, Agoram BM, van der Graaf PH. Aston PJ, et al. J Theor Biol. 2011 Jul 21;281(1):113-21. doi: 10.1016/j.jtbi.2011.04.030. Epub 2011 May 6. J Theor Biol. 2011. PMID: 21557949

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters